Inovio Pharmaceuticals, INC Form 4 insider transactions

Director David B. Weiner reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Director Wendy Yarno reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock through restricted stock units.

Director Lota S. Zoth reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Director Roger D. Dansey exercised stock options in Inovio Pharmaceuticals on May 15, 2024.

CEO Jacqueline E. Shea exercised restricted stock units and sold shares of Inovio Pharmaceuticals to cover tax obligations on May 15, 2024.

Director Roger D. Dansey exercised stock options to acquire 1,000 shares of Inovio Pharmaceuticals common stock on May 13, 2024.

CEO Jacqueline Elizabeth Shea reports acquisition and disposal of Inovio Pharmaceuticals stock related to restricted stock units.

Director David B. Weiner reports the vesting and acquisition of common stock through restricted stock units.

CEO Jacqueline Elizabeth Shea reports transactions involving Inovio Pharmaceuticals stock, including the vesting of restricted stock units, withholding of shares for tax obligations, and the grant of new stock options.

Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the vesting and settlement of restricted stock units and the acquisition of new stock options.

CFO of Inovio Pharmaceuticals, Peter Kies, reports transactions involving common stock and restricted stock units, including vesting, tax withholding, and option grants.

Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, reports the acquisition of stock options and restricted stock units.